Biosimilar tenecteplase versus alteplase in acute ischemic stroke: A real world study

Bhatia, Rohit; Mohan, Ayush; Komakula, Snigdha; Murali, Suhas; Anand, Pooja; Shah, Dyuti; Vishnu, V.Y.; Pandit, AwadhKishor; Agarwal, Ayush; Vibha, Deepti; Singh, Meharban; Srivastava, MV Padma

doi:10.4103/aian.aian_754_22

Cited by 4 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biosimilar Tenecteplase versus alteplase was evaluated in Indian patients 85 with AIS, and no difference was found in efficacy and safety both. 86, 87…”

Section: Right Drug: Thrombolysismentioning

confidence: 99%

“…99 Trace-2 trial: Tenecteplase was as effective as alteplase in patients with ischemic stroke who could not undergo or refused endovascular thrombectomy. 84 Biosimilar Tenecteplase versus alteplase was evaluated in Indian patients 85 with AIS, and no difference was found in efficacy and safety both. 86, 87 The retrospective study involved collecting data from consecutive AIS patients who reported Tenecteplase at a dose of 0.2 mg/kg is safe and efficacious for the thrombolysis of AIS during the 4.5-hour window period.…”

Section: Right Drug: Thrombolysismentioning

confidence: 99%

“…82 Tenecteplase has a 15 times higher fibrin specificity and a longer half-life than alteplase. 83 Following is evidence comparing both thrombolytics 85 with AIS, and no difference was found in efficacy and safety both. 86,87 • The retrospective study involved collecting data from consecutive AIS patients who reported Tenecteplase at a dose of 0.2 mg/kg is safe and efficacious for the thrombolysis of AIS during the 4.5-hour window period.…”

Section: Right Drug: Thrombolysismentioning

confidence: 99%

See 2 more Smart Citations

Expert Consensus on Improving Stroke Care Ecosystem in India

Srivastava,

Mehndiratta,

Kaul

et al. 2024

Journal of Stroke Medicine

View full text Add to dashboard Cite

The stroke burden in India is alarmingly high compared to Western industrialised countries, necessitating immediate action to develop stroke systems of care. Tailored stroke-prevention strategies, adequate resource allocation for stroke management and research, and increased awareness of specialised care in acute Stroke are critical. The COVID-19 pandemic has underscored the need for improved healthcare delivery and infrastructure. To address the rising stroke burden in India, comprehensive strategies encompassing prevention, awareness, specialised care and governmental support are urgently required. While the concept of ‘stroke-ready centres’ has emerged, their limited availability hinders widespread benefits. This expert consensus examines the current state of stroke care in India, identifies challenges, and proposes strategies to enhance stroke care systems. It offers valuable insights into stroke management at different levels, empowering healthcare professionals and administrators to assess their existing systems and make necessary improvements. Special attention is given to the role of physicians, including the use of thrombolytic therapies like Tenecteplase, in reducing the stroke burden and improving outcomes across the country. Significant strides can be made in stroke management and care in India by addressing these critical areas.

show abstract

“…Biosimilar Tenecteplase versus alteplase was evaluated in Indian patients 85 with AIS, and no difference was found in efficacy and safety both. 86, 87…”

Section: Right Drug: Thrombolysismentioning

confidence: 99%